These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30067199)

  • 1. [Is it possible to use immune checkpoint inhibitors in patients with autoimmune or inflammatory disease?].
    Danlos FX; Lambotte O
    Med Sci (Paris); 2018; 34(6-7):516-518. PubMed ID: 30067199
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biological response modifiers in the treatment of immunoinflammatory diseases].
    Skov L; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2120-6. PubMed ID: 18565292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
    Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
    Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New biological drugs for the treatment of chronic inflammatory diseases].
    Skov L; Hegedüs L; Madsbad S; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2162. PubMed ID: 18572482
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biological drugs in the treatment of immunoinflammatory diseases].
    Nielsen OH; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2103. PubMed ID: 18565288
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders.
    Cvetkovic I; Stosic-Grujicic S
    Int Immunopharmacol; 2006 Oct; 6(10):1527-34. PubMed ID: 16919824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapies: what and when?
    Johnston SL
    J Clin Pathol; 2007 Jan; 60(1):8-17. PubMed ID: 17213345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
    Perosa F; Prete M; Racanelli V; Dammacco F
    J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V; Mydlarski PR
    Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in the treatment of autoimmune haematological disorders.
    Provan D; Newland AC; Amadori S; Stasi R
    Br J Haematol; 2008 Oct; 143(2):294; author reply 295. PubMed ID: 18752592
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of biological agents in immune-mediated inflammatory diseases.
    Efthimiou P; Markenson JA
    South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal antibodies. Principles, generation, application, and side effects].
    Sack U; Emmrich F
    Internist (Berl); 2008 Aug; 49(8):919-20, 921-4, 926-8. PubMed ID: 18587546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update upon efficacy and safety of TNF-α inhibitors.
    Murdaca G; Colombo BM; Cagnati P; Gulli R; Spanò F; Puppo F
    Expert Opin Drug Saf; 2012 Jan; 11(1):1-5. PubMed ID: 22010813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy with intravenous gammaglobulins in systemic inflammatory autoimmune diseases: new indications?].
    Sánchez-Ramón S; Valor L
    Med Clin (Barc); 2014 Aug; 143(3):130-3. PubMed ID: 24480286
    [No Abstract]   [Full Text] [Related]  

  • 15. B cell depletion: on the rise.
    Hinze CH; Grom AA
    J Pediatr; 2007 Apr; 150(4):335-7. PubMed ID: 17382106
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab.
    Schumann T; Schmidt E; Booken N; Goerdt S; Goebeler M
    Acta Derm Venereol; 2009; 89(1):101-2. PubMed ID: 19197558
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor necrosis factor inhibitors: following best practice.
    White B
    Manag Care; 2005 May; 14(5 Suppl):17-23. PubMed ID: 15962833
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and immune diseases: what is at the summit?
    Cushley W
    Drug Discov Today; 2005 Jun; 10(11):752-4. PubMed ID: 15922932
    [No Abstract]   [Full Text] [Related]  

  • 20. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.